- Home
- RMMZ vs NOTV Comparison
RMMZ vs NOTV Comparison
Compare RMMZ & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMMZ
- NOTV
- Stock Information
- Founded
- RMMZ 2022
- NOTV 1974
- Country
- RMMZ United States
- NOTV United States
- Employees
- RMMZ N/A
- NOTV N/A
- Industry
- RMMZ Investment Managers
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- RMMZ Finance
- NOTV Health Care
- Exchange
- RMMZ Nasdaq
- NOTV Nasdaq
- Market Cap
- RMMZ 126.3M
- NOTV 126.3M
- IPO Year
- RMMZ N/A
- NOTV 1997
- Fundamental
- Price
- RMMZ $15.41
- NOTV $4.27
- Analyst Decision
- RMMZ
- NOTV Strong Buy
- Analyst Count
- RMMZ 0
- NOTV 3
- Target Price
- RMMZ N/A
- NOTV $5.92
- AVG Volume (30 Days)
- RMMZ 25.6K
- NOTV 1.2M
- Earning Date
- RMMZ 01-01-0001
- NOTV 02-05-2025
- Dividend Yield
- RMMZ 7.33%
- NOTV N/A
- EPS Growth
- RMMZ N/A
- NOTV N/A
- EPS
- RMMZ 0.82
- NOTV N/A
- Revenue
- RMMZ N/A
- NOTV $490,739,000.00
- Revenue This Year
- RMMZ N/A
- NOTV $7.14
- Revenue Next Year
- RMMZ N/A
- NOTV $5.73
- P/E Ratio
- RMMZ $19.41
- NOTV N/A
- Revenue Growth
- RMMZ N/A
- NOTV N/A
- 52 Week Low
- RMMZ $12.92
- NOTV $1.23
- 52 Week High
- RMMZ $16.99
- NOTV $11.42
- Technical
- Relative Strength Index (RSI)
- RMMZ 54.64
- NOTV 49.19
- Support Level
- RMMZ $15.17
- NOTV $3.87
- Resistance Level
- RMMZ $15.37
- NOTV $4.67
- Average True Range (ATR)
- RMMZ 0.17
- NOTV 0.54
- MACD
- RMMZ 0.06
- NOTV -0.10
- Stochastic Oscillator
- RMMZ 91.03
- NOTV 22.22
About RMMZ RiverNorth Managed Duration Municipal Income Fund II Inc.
RiverNorth Managed Duration Municipal Income Fund II Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.